- Mild cases of ARDS will be included in a two-arm protocol, to receive 500 mcg of
roflumilast daily up to 28 days (FDA approved dose for COPD) plus standard of care
versus standard of care alone.
- Approximately 76 hospitalized patients with ARDS will be enrolled in this study.
- Eligible patients will be randomized at ratio of (1:1) to receive either roflumilast
plus standard of care or standard of care alone.